DOI: 10.1002/alz.080904 ISSN: 1552-5260

Amyloid Reduction: Donanemab Perspective

John R. Sims
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Geriatrics and Gerontology
  • Neurology (clinical)
  • Developmental Neuroscience
  • Health Policy
  • Epidemiology

Abstract

Background

Methods

Result

Conclusion

More from our Archive